Massimo Giachetti
PHAXIAM Therapeutics (NASDAQ:PHXM) received Nasdaq notice that it has regained compliance with the listing rule as the price of the ADS was above $1.00 for 10 consecutive business days from September 18 through September 29, 2023.
On October 7, 2022, PHAXIAM, formerly Erytech Pharma, received Nasdaq notice that the closing bid price was less than $1.00 per ADS for the prior 30 consecutive business day period and the company no longer satisfied the minimum bid price rule.